Health and Fitness Health and Fitness
Thu, April 26, 2012
[ Thu, Apr 26th 2012 ] - Market Wire
Plant The Seed Movie
Wed, April 25, 2012
[ Wed, Apr 25th 2012 ] - Market Wire
Board Changes
[ Wed, Apr 25th 2012 ] - Market Wire
30 a.m. ET

DURECT Corporation Invites You to Join its First Quarter 2012 Earnings Conference Call


Published on 2012-04-25 13:26:11 - Market Wire
  Print publication without navigation


DURECT Corporation Invites You to Join its First Quarter 2012 Earnings Conference... -- CUPERTINO, Calif., April 25, 2012 /PRNewswire/ --

DURECT Corporation Invites You to Join its First Quarter 2012 Earnings Conference Call

[ ]

CUPERTINO, Calif., April 25, 2012 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: [ DRRX ]) first quarter 2012 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 3, 2012 at 4:30 pm Eastern Time (1:30 pm Pacific Time).

(Logo: [ http://photos.prnewswire.com/prnh/20020717/DRRXLOGO ])

A live audio webcast of the presentation will be available by accessing DURECT's homepage at [ http://www.durect.com ] and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit [ www.durect.com ].

NOTE: POSIDUR™, SABER®, ORADUR®, TRANSDUR®, and ELADUR® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation

[ Back to top ]

RELATED LINKS
[ http://www.durect.com ]